Remove DNA Remove Marketing Remove Radiology
article thumbnail

INOVIO Announces Publication of Phase 1 Data from its COVID-19 DNA Vaccine Candidate, INO-4800 in The Lancet’s EClinicalMedicine

The Pharma Data

” Dr. Stanley Plotkin , Professor Emeritus at The Wistar Institute, said, “INOVIO’s DNA vaccine appeared to be quite safe with few significant reactions but yet induced both antibody and T cell responses to SARS-CoV-2.” About INOVIO’s DNA Medicines Platform. mg and 2.0

DNA 40
article thumbnail

Patient Safety and Radiopharmaceuticals Administration: Minimizing Radiation Exposure and Risks

Worldwide Clinical Trials

Genetic Factors : Certain genetic mutations, such as those in DNA repair genes, can affect how cells respond to radiation. Individuals with familial cancer syndrome may have inherited mutations that predispose them to cancer development, affecting genes involved in DNA repair and cell cycle regulation.

Hormones 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Novartis expands in radio-oncology again with $1.3bn Artios alliance

pharmaphorum

The collaboration will focus on combining Artios’ DNA damage response (DDR) drug candidates with Novartis’ radioligand therapies, which consist of tumour-targeting molecules carrying radioactive isotopes that can deliver a cell-killing dose of radiation to malignant cells. It’s also providing research funding.

DNA 52
article thumbnail

How Advanced Diagnostics are Shaping the Future of Precision Medicine and Gene Therapy

Cloudbyz

This revolution is enabling the growth of innovative biomarker-based precision medicine and cell and gene therapy, transforming both clinical research and post-market care. Liquid biopsies, for example, allow non-invasive monitoring of cancer progression and response to treatment by analyzing circulating tumor DNA (ctDNA) in blood samples.

article thumbnail

Behind the Breakthroughs and Practice-Changing Advances: Insights from ESMO 2024

Intouch Solutions

Both manufacturers and marketers need to understand how HCPs make these decisions and which patients are likely to benefit from one type of treatment over another. ctDNA: New data was presented demonstrating major advances in the understanding of circulating tumor DNA (ctDNA). Will it revolutionize solid tumor staging?

DNA 59
article thumbnail

Bayer acquires Noria and PSMA Therapeutics to expand portfolio in prostate cancer

The Pharma Data

Noria was founded by Dr. John Babich, Chief, Radiopharmaceutical Sciences in Radiology at Weill Cornell Medicine. It has been demonstrated to inflict difficult to repair damage to tumor cells by inducing DNA double strand breaks. Compared to beta radiation, alpha radiation has a higher potency and shorter range.

article thumbnail

Unveiling Potential: Exploring Alpha Emitter Radiopharmaceuticals

XTalks

Regulatory bodies have demonstrated preparedness for the surge in radiopharmaceuticals as evidenced by inaugural Chemistry, Manufacturing and Controls (CMC) Development and Readiness Pilot (CDRP) programs to expedite commercial manufacturing, US Food and Drug Administration (FDA) approvals and marketing authorizations.

DNA 66